Literature DB >> 3114911

Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction.

L O Almér, H Ohlin.   

Abstract

Myocardial infarction is frequently caused by acute coronary thrombosis. A previous study in patients three years after myocardial infarction has shown twice as high concentrations of the rapid inhibitor of plasminogen activator (t-PAI) as in healthy controls. The present study involves 29 patients with acute onset of myocardial infarction. Already on admission the mean concentration of t-PAI was 16.5 +/- 7.4 units/ml as compared to 7.5 +/- 2.3 in healthy controls. It is presently unknown if moderately elevated t-PAI levels contribute to a delay of the spontaneous thrombolysis of the coronary occlusion, thus promoting the development of myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114911     DOI: 10.1016/0049-3848(87)90147-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  16 in total

1.  The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.

Authors:  Ayman A El Menyar; O M Altamimi; Mohamed M Gomaa; Zainab Fawzy; M O Abdel Rahman; Abdulbari Bener
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

2.  Modulation of fibrinolysis by ionizing radiation.

Authors:  J S Rao; A Rayford; M Yamamoto; K K Ang; P Tofilon; R Sawaya
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 3.  Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 4.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction.

Authors:  A Sinkovic
Journal:  Clin Cardiol       Date:  2000-07       Impact factor: 2.882

7.  Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.

Authors:  R P Gray; J S Yudkin; D L Patterson
Journal:  Br Heart J       Date:  1993-03

8.  Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

Authors:  M S Sawdey; D J Loskutoff
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 9.  Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.

Authors:  I Juhan-Vague; M C Alessi; P Vague
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

10.  Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy.

Authors:  J Grulich-Henn; K Loechelt; W Speiser; G Müller-Berghaus
Journal:  Blut       Date:  1989-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.